Roche’s fast-growing eye drug Vabysmo set for EU approval
Roche has been trumpeting the rapid uptake of its new eye disease drug Vabysmo as it takes on Regeneron and Bayer’s mighty Eylea in the […]
ophthalmology
Ophthalmic Drugs Conference
SAE Media Group’s 5th Annual Ophthalmic Drugs Conference 21 – 22 November 2022 | London, UK http://www.ophthalmicdrugs.com/PharmaPhorum Delving into advanced R&D and Delivery of Ocular […]
Could an eye test spot people at risk of heart attacks?
An analysis of images of the retina harvested from the UK Biobank resource suggests that it may be possible to identify individuals at risk of […]
2nd Integrin-Targeted Drug Development Summit
In collaboration with leading integrin drug developers, including Genentech, 7 Hills Pharma, and Pfizer, the 2nd Integrin-Targeted Drug Development Summit is designed for industry leaders to unite and outline clinical […]
Oxurion craters as failed trial cuts its pipeline down to one
Shares in Belgian biotech Oxurion are taking a hammering this morning after it reported that one of its drugs for diabetic eye disease had failed […]
Longer-term data raise prospects for Apellis’ pegcetacoplan
Apellis chances of getting regulatory approval for pegcetacoplan, its drug candidate for sight-robbing disease geographic atrophy (GA), may have been heightened by new follow-up data […]
Oxurion reports stronger data for diabetic eye disease drug
Belgian biotech Oxurion has revealed new data from a phase 2 trial of its plasma kallikrein inhibitor THR-149, in development for people with diabetic macular […]
Roche grabs FDA okay for would-be blockbuster eye drug faricimab
The FDA has approved Roche’s much-anticipated faricimab for two major causes of blindness, setting up a market clash with Bayer and Regeneron’s market leading drug […]
AbbVie prices first presbyopia drug Vuity at $80 per month
AbbVie has ended speculation about what it will charge for its newly-approved Vuity therapy for presbyopia, a sight condition characterised by difficulty in focusing on […]
Sanofi winds $40m into UK gene therapy firm Gyroscope
French drugmaker Sanofi has made a $40 million investment in Gyroscope Therapeutics, with another $20 million potentially on offer as the UK biotech advances its […]
AbbVie claims first FDA okay for presbyopia drug therapy
The FDA has approved the first and so far only pharmacological treatment for presbyopia, a sight condition that typically starts in middle age and involves […]
Luminopia scores FDA approval for TV-based amblyopia therapy
Hard on the heels of some impressive clinical trial results, Luminopia has won FDA approval for its digital therapeutic (DTx) for amblyopia or lazy eye […]
FDA clears Roche’s Susvimo implant for eye disease wet AMD
Roche’s Genentech unit has won FDA approval for Susvimo, an implant for eyesight-robbing disease wet age-related macular degeneration (AMD) that gives patients an alternative to […]
FDA OKs first biosimilar of Roche’s blockbuster AMD drug Lucentis
Samsung Bioepis and Biogen have claimed the first FDA approval for a biosimilar version of Roche and Novartis’ Lucentis (ranibizumab) for leading causes of blindness, […]
Luminopia’s digital therapy for lazy eye aces clinical trial
A digital therapeutic (DTx) for amblyopia – sometimes known as lazy eye – has been shown to improve vision correction over standard therapy in a […]
AbbVie spies potential in Regenxbio eye disease gene therapy
AbbVie has expanded its ophthalmology pipeline via a licensing deal with Regenxbio, paying $370 million upfront to get its hands on a gene therapy for […]
Apellis reports mixed data with eye drug, but plans to file anyway
Apellis Pharma’s has reported mixed results with its lead drug pegcetacoplan in geographic atrophy (GA) – a major cause of blindness – with one hit […]
Europe has its first Lucentis biosimilar, Samsung Bioepis’ Byooviz
Novartis and Roche’s big-selling eye drug Lucentis has its first biosimilar competitor in Europe, after the European Commission approved Samsung Bioepis’ copycat drug Byooviz. Byooviz […]
Novartis says trials back Beovu safety in diabetic eye disease
There is plenty of evidence that Novartis’ ophthalmology drug Beovu can match its rivals when it comes to efficacy, with less frequent dosing, but the […]
Novartis says trials back Beovu safety in diabetic eye disease
There is plenty of evidence that Novartis’ ophthalmology drug Beovu can match its rivals when it comes to efficacy, with less frequent dosing, but the […]
FDA starts review of Roche’s eye disease drug, setting up 2022 verdict
The FDA has started a priority review of Roche’s bispecific antibody faricimab for two major causes of blindness, preparing for a market showdown with Bayer […]
Allergen builds case for first drug therapy for presbyopia
If you are in middle aged and find you have to hold your phone at arm’s length to read, you may have presbyopia – a […]
Dopavision raises €12m for DTx to tackle myopia epidemic
Digital therapeutics (DTx) startup Dopavision has raised funding to develop its lead product, an app designed to slow the progression of myopia – or short-sightedness […]
Biogen’s ambitions in gene therapy hit by another failed pivotal trial
When Biogen acquired Nightstar Therapeutics in 2019, it added a pair inherited retinal disorder (IRD) gene therapies that it hoped would accelerate a push into […]
Novartis halts three trials of Beovu eye drug on safety concerns
Prospects for Novartis’ ophthalmology drug Beovu have taken another dive after the drugmaker reported toxicity issues in a new phase 3 trial in wet age-related […]
Biogen’s eye disease gene therapy fails ahead of FDA Alzheimer’s ruling
Biogen has downbeat news about its gene therapy for the rare inherited eye disease, X-linked retinitis pigmentosa, announcing the shot failed to meet its target […]
Aura raises $80m to develop its virus-like cancer drugs
US biotech Aura Biosciences has closed an oversubscribed financing, raising $80 million to help take its lead virus-like drug conjugate (VDC) for a cancer that […]
Two biotechs target dry eye disease after Novartis’ Xiidra problems
The pipeline for dry eye disease drugs is beginning to heat up, with two biotechs announcing key developments, aiming to disrupt a market led by […]
UK patient group warns COVID could limit access to Novartis’ new eye drug
NICE has recommended regular NHS funding for Novartis’ long-acting eye drug Beovu (brolucizumab) in England and Wales – but a patient group warned that access […]
Roche targets wet AMD with faricimab and its 16-week regimen
Twin late-stage trials of Roche’s ophthalmology drug faricimab have hit the mark in “wet” age-related macular degeneration trial, as the company’s challenge to rivals from […]
Roche set to file ophthalmology drug faricimab in DME
Roche looks set to mount a challenge to Bayer’s ophthalmology drug Eylea in 2021 after its faricimab antibody showed comparable results in diabetic macular oedema […]
RetinAI Collaborates with Novartis to Provide AI Solutions in Ophthalmology
Shots: RetinAI signs a multi-year collaboration with Novartis under which RetinAI’s IT solutions and AI tools will be employed to support multiple projects in ophthalmology […]
Novartis signs ophthalmology AI deal with RetinAI
Novartis has signed a multi-year agreement with RetinAI, which will see the companies work together to use artificial intelligence (AI) tools to support ophthalmology and […]
Janssen adds Hemera’s AMD gene therapy to pipeline
Johnson & Johnson’s pharma unit Janssen has bought rights to an investigational gene therapy for a severe form age-related macular degeneration from specialist biotech Hemera […]
Poor Vision and Senior Falls: An Ophthalmologist’s Perspective
Poor Vision and Senior Falls: An Ophthalmologist’s Perspective Aging is associated with increased risk of poor vision. It, in turn, increases risk for senior falls. […]
Novartis taps smartpatient for app to support wet AMD patients
German digital health company smartpatient is adding a new section of its MyTherapy app providing information on wet age-related macular degeneration (AMD), a leading cause […]
FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar
Novartis/Genentech’s eye drug Lucentis could be the next big blockbuster to face competition from cheaper biosimilars after its US patent expired this year – and […]
Novartis keeps a close eye on gene therapy with Vedere Bio buy
Already a major player in gene therapy, Novartis has swooped on US startup Vedere Bio in a $280 million deal that builds its position in […]
SparingVision raises €44.5m for retinitis pigmentosa gene therapy
French biotech SparingVision has raised 44.5 million euros ($52.7 million) to develop its gene therapy for a rare ocular disease. The round was led by […]
Samsung Bioepis and Biogen Announce EMA Filling Acceptance of SB11 (biosimilar, Lucentis)
Shots: EMA has accepted to review the Marketing Authorisation Application for SB11, a proposed biosimilar referencing Lucentis (ranibizumab). If approved, SB11 will join a growing […]
Dealing with a Rare Eye Disease in the Midst of COVID19
Dealing with a Rare Eye Disease in the Midst of COVID19 After being diagnosed with a rare eye disease, a doctor learns the best treatment […]
